Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Role of Artificial Intelligence in Prostate Cancer Detection via MRI: Insights and Future Perspectives from the ESUR Prostate MRI Working Group

  • By

  • Renato Cuocolo

  • Andrea Ponsiglione

  • Georgios Agrotis

  • Tristan Barrett

  • Giorgio Brembilla

  • Iztok Caglic

  • Hanna Falińska

  • Charlie Alexander Hamm

  • Emanuele Messina

  • Tobias Penzkofer

  • Raphaële Renard-Penna

  • Olivier Rouvière

  • Luca Russo

  • Evis Sala

  • Johannes Uhlig

  • Anwar R. Padhani

  • Maarten de Rooij

  • September 18, 2026

Share

  • 1

    AI is advancing in prostate MRI, transitioning from radiomic models to deep learning systems that enhance diagnostic workflows.

  • 2

    Standalone AI systems have shown potential to match or exceed radiologists' performance in detecting clinically significant prostate cancer.

  • 3

    Challenges remain in the clinical implementation of AIaMDs, including validation data shortages and complexities in human-AI interactions.

  • 4

    Real-world evidence for AIaMDs is limited, with most studies focusing on standalone performance rather than clinical efficacy.

  • 5

    The ESUR Prostate MRI Working Group emphasizes the need for post-market surveillance and targeted research to optimize AI device use.

Original Source(s)

Current status and future directions of AI in prostate cancer detection on MRI: a special report from the ESUR prostate MRI working group authors

  • by Renato Cuocolo, Andrea Ponsiglione, Georgios Agrotis, Tristan Barrett, Giorgio Brembilla, Iztok Caglic, Hanna Falińska, Charlie Alexander Hamm, Emanuele Messina, Tobias Penzkofer, Raphaële Renard-Penna, Olivier Rouvière, Luca Russo, Evis Sala, Johannes Uhlig, Anwar R. Padhani, Maarten de Rooij

  • September 18, 2026

Related Content

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min
The evolution of RTOG and NRG Oncology CNS tumors clinical trials

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC